From a pathophysiological perspective, since the primary actions of metformin significantly reduce circulating glucose and plasma insulin, hence improving insulin resistance, it may be beneficial for reducing the risk of diabetes-related cancer incidents [37]. The gene discussed is INS; the disease is cancer.